Literature DB >> 16236916

The role of timely intervention in middle lobe syndrome in children.

Kostas N Priftis1, Despina Mermiri, Athina Papadopoulou, Michael B Anthracopoulos, George Vaos, Polyxeni Nicolaidou.   

Abstract

STUDY
OBJECTIVES: Middle lobe syndrome (MLS) in children is characterized by a spectrum of clinical and radiographic presentations, from persistent or recurrent atelectasis to pneumonitis and bronchiectasis of the right middle lobe (RML) and/or lingula. This study was undertaken to evaluate the effect of early intervention, including fiberoptic bronchoscopy (FOB), in the development of bronchiectasis in MLS.
DESIGN: Children with atelectasis of the RML and/or lingula persisting for > 1 month or recurring two or more times despite conventional treatment underwent high-resolution CT (HRCT) scanning and FOB. Appropriate treatment and follow-up were provided, and the effect of the duration of symptoms on clinical outcome and the development of bronchiectasis was investigated. The patient cohort was retrospectively reviewed. PATIENTS: We evaluated 55 children with MLS. The median age at diagnosis, duration of symptoms, and duration of clinical deterioration before diagnosis were 5.5 years (range, 3 months to 12 years), 14.5 months (range, 3 to 48 months), and 8 months (range, 3 to 36 months), respectively. MEASUREMENTS AND
RESULTS: FOB revealed marked obstruction in two children (ie, a foreign body and an endobronchial tumor) and positive findings for a culture of BAL fluid in 49.1% of patients. The remaining 53 patients were followed up for a median duration of 24 months (range, 5 to 96 months). The clinical outcome was "cure" in 60.4% of patients, "improvement" in 32.1% of patients, and "no change" in the remaining patients. Bronchiectasis was documented prior to FOB by HRCT scan in 15 patients (27.3%). The duration of the deterioration of symptoms prior to presentation positively correlated with the development of bronchiectasis (p = 0.03) and an unfavorable clinical outcome (ie, improvement or no change) [p = 0.02]; a positive correlation was also found between the duration of symptoms and the development of bronchiectasis (p = 0.04).
CONCLUSIONS: Timely medical intervention in patients with MLS that includes FOB with BAL prevents bronchiectasis that may be responsible for an ultimately unfavorable outcome.

Entities:  

Mesh:

Year:  2005        PMID: 16236916     DOI: 10.1378/chest.128.4.2504

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  10 in total

1.  47 year old patient with pseudo-asthma.

Authors:  Bulent Altinsoy; Nejat Altinta; Zeynep Sonmez Celik
Journal:  Oman Med J       Date:  2011-01

Review 2.  A review of non-cystic fibrosis pediatric bronchiectasis.

Authors:  Eric J Boren; Suzanne S Teuber; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2008-04       Impact factor: 8.667

3.  Bronchoalveolar lavage in children with inflammatory and non inflammatory lung disease.

Authors:  D Gidaris; F Kanakoudi-Tsakalidou; D Papakosta; V Tzimouli; A Taparkou; M Ventouri; I Tsanakas
Journal:  Hippokratia       Date:  2010-04       Impact factor: 0.471

4.  Chronic atelectasis of the left lower lobe: a clinicopathological condition equivalent to middle lobe syndrome.

Authors:  Abdel-Mohsen Hamad; Elsayed Elmistekawy; Elatafy Elatafy
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-07-02

5.  Chest MR imaging in the follow-up of pulmonary alterations in paediatric patients with middle lobe syndrome: comparison with chest X-ray.

Authors:  F Fraioli; G Serra; G Ciarlo; V Massaccesi; S Liberali; A Fiorelli; F Macrì; C Catalano
Journal:  Radiol Med       Date:  2012-10-22       Impact factor: 3.469

6.  Massive benign pericardial cyst presenting with simultaneous superior vena cava and middle lobe syndromes.

Authors:  Pankaj Kaul; Kalyana Javangula; Shahme A Farook
Journal:  J Cardiothorac Surg       Date:  2008-05-21       Impact factor: 1.637

7.  Surgical treatment of right middle lobe syndrome in children.

Authors:  A Sehitogullari; F Sayir; U Cobanoglu; S Bilici
Journal:  Ann Thorac Med       Date:  2012-01       Impact factor: 2.219

8.  The Saudi Thoracic Society guidelines for diagnosis and management of noncystic fibrosis bronchiectasis.

Authors:  Hamdan Al-Jahdali; Abdullah Alshimemeri; Abdullah Mobeireek; Amr S Albanna; Nehad N Al Shirawi; Siraj Wali; Khaled Alkattan; Abdulrahman A Alrajhi; Khalid Mobaireek; Hassan S Alorainy; Mohamed S Al-Hajjaj; Anne B Chang; Stefano Aliberti
Journal:  Ann Thorac Med       Date:  2017 Jul-Sep       Impact factor: 2.219

9.  Prevalence and course of disease after lung resection in primary ciliary dyskinesia: a cohort & nested case-control study.

Authors:  Panayiotis Kouis; Myrofora Goutaki; Florian S Halbeisen; Ifigeneia Gioti; Nicos Middleton; Israel Amirav; Angelo Barbato; Laura Behan; Mieke Boon; Nagehan Emiralioglu; Eric G Haarman; Bulent Karadag; Cordula Koerner-Rettberg; Romain Lazor; Michael R Loebinger; Bernard Maitre; Henryk Mazurek; Lucy Morgan; Kim Gjerum Nielsen; Heymut Omran; Ugur Özçelik; Mareike Price; Andrzej Pogorzelski; Deborah Snijders; Guillaume Thouvenin; Claudius Werner; Zorica Zivkovic; Claudia E Kuehni; Panayiotis K Yiallouros
Journal:  Respir Res       Date:  2019-09-18

10.  Diagnosing and preventing chronic suppurative lung disease (CSLD) and bronchiectasis.

Authors:  A B Chang; C A Byrnes; M L Everard
Journal:  Paediatr Respir Rev       Date:  2010-12-04       Impact factor: 2.726

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.